Imaging right ventricular function to predict outcome in pulmonary arterial hypertension
Introduction
It has been realized in recent years that right ventricular (RV) function is a major determinant of functional state, exercise capacity and survival in patients with pulmonary arterial hypertension (PAH) [1]. However, how to measure RV function and what variables might be most clinically relevant at the bedside remains uncertain [1], [2].
The gold standard measure of RV systolic functional adaptation to increased loading conditions is end-systolic elastance (Ees) (or end-systolic pressure (ESP) divided by end-systolic volume (ESV)), corrected for arterial elastance (Ea) (or stroke volume (SV) divided by ESP). The Ees/Ea ratio defines RV–arterial coupling, or the matching of contractility to afterload. Ees is a measure of RV contractility and unlike other measures of RV function is load independent. Ea is a measure of the afterload faced by the RV and incorporates resistance, compliance and impedance of the pulmonary circulation. The optimal balance between RV work and oxygen consumption occurs at an Ees/Ea ratio of 1.5–2 [1], [2].
The reference method for the determination of Ees requires instantaneous and simultaneous measurements of RV pressure and volume and generation of a family of pressure–volume loops at decreasing venous return [3]. This is not practical at the bedside. However Ees can also be estimated from a single P–V loop [4]. This method relies on the calculation of a maximum RV pressure (Pmax) from the extrapolation of early and late systolic portions of a RV pressure curve and the continuous recording of RV pressure and relative change in volume to define ESP and ESV. From these, Ees and Ea are easily calculated. The estimation of RV–arterial coupling by an Ees/Ea ratio can further be simplified for pressure and expressed as a SV/ESV ratio [5], i.e. the volume method. Alternatively the ratio can be simplified for volumes and expressed as Pmax divided by mean pulmonary artery pressure (mPAP), taken as a surrogate for ESP, minus 1 [6], i.e. the pressure method. A RV pressure curve is easily obtained during a right heart catheterization. RV volumes are ideally determined by magnetic resonance imaging (CMR).
From RV volumes it is naturally also easy to calculate a SV and an ejection fraction (EF) as SV/EDV. Cardiac CMR studies have shown that decreased SV and RV EF are predictive of poor outcome [7], and that a deterioration in RV EF during PAH therapy predicts a poor survival irrespective of improvements in pulmonary vascular resistance (PVR) [8]. However, EF is preload-dependent while Ees/Ea is theoretically not. Therefore, estimates of Ees should be superior in determining clinical state and outcome. Accordingly, a recent study on a limited number of patients referred for investigation of PH showed Ees/Ea estimated by SV/ESV to be an independent predictor of outcome while EF was not [9].
We therefore investigated the prognostic utility of RV–arterial coupling determined by both the volume and the pressure methods, compared to more usual determinations of EF and right heart catheterization-derived RAP and SV in a large cohort of patients with PAH, and in addition examined changes over time of these measurements with targeted therapies and their impact on survival.
Section snippets
Methods
We identified 140 treatment naïve incident cases of PAH diagnosed between January 2004 and April 2014 at the Scottish Pulmonary Vascular Unit, Glasgow. Patients were included after multidisciplinary evaluation based on right heart catheterization, echocardiography, pulmonary function testing and CT scan of thorax. All patients underwent invasive measurements and cardiac CMR within 72 h and received pulmonary vasodilator therapy in accordance with guidelines [10]. In 84/140 patients, RV pressures
Population characteristics
Of the 140 PAH patients included in the study, 61 deaths occurred in the follow-up period (median survival 2086 days). Table 1 describes the characteristics of the whole population and the 84 PAH patients with RV pressure trace analysis in comparison to 22 control patients with mPAP < 25 mm Hg. PAH patients had a mPAP range of 28–101 mm Hg and demonstrated impaired RVEF, low SVI and increased RV volumes and mass.
There were no significant differences between SVI calculated as cardiac index/heart rate
Discussion
The present results show that CMR imaging of RV volumes allows for the prediction of outcome in PAH by RV function defined either as EF or SV/ESV. In this study, right heart catheterization-derived estimates of RV function such as RAP, SV or PVR or SV/PP did not independently predict outcome. Furthermore, there was no added value of combining invasive measurements of pressure with non-invasive measurements of volumes to assess RV–arterial coupling.
The present study confirms previous reports
Conclusion
RV function to predict survival in PAH is best determined by CMR measurements of SV/ESV or EF, without added value of invasively measured RV pressure measurements.
Disclosures
Dr. Brewis has received assistance with travel and conference registration from Actelion, Pfizer and GSK. Dr. Johnson has received honoraria, assistance with travel and research projects from Actelion, Bayer, and GSK. Professor Peacock has received honoraria, assistance with travel and unrestricted research grants from Actelion, Bayer, GSK, Pfizer and United Therapeutics.
Dr. Bellofiore, Dr. Vanderpool, Dr. Chesler and Professor Naeije report no relationships that could be construed as a
Funding sources
Dr. Vanderpool's work is supported by a NIH T32 grant (T32 HL110849). Dr Chesler's work is supported by a NIH grant 1R01HL105598.
Part of this work has previously been published in abstract form:
Brewis MJ, Naeije R, Bellofiore A, Chesler N and Peacock AJ. Cardiac MRI derived right ventriculo-arterial coupling in pulmonary hypertension as a predictor of survival. Eur Resp J 2014; 44: Suppl 58, P2300.
References (31)
- et al.
Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology
J. Am. Coll. Cardiol.
(2013) - et al.
Accurate assessment of load-independent right ventricular systolic function in patients with pulmonary hypertension
J. Heart Lung Transplant.
(2013) - et al.
Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy
J. Am. Coll. Cardiol.
(2011) - et al.
Definitions and diagnosis of pulmonary hypertension
J. Am. Coll. Cardiol.
(2013) - et al.
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
J. Am. Coll. Cardiol.
(2002) - et al.
Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension
Am. J. Cardiol.
(2011) Assessment of right ventricular function in pulmonary hypertension
Curr. Hypertens. Rep.
(2015)- et al.
Instantaneous pressure–volume relationship of the canine right ventricle
Circ. Res.
(1979) - et al.
Single-beat estimation of right ventricular end-systolic pressure–volume relationship
Am. J. Physiol. Heart Circ. Physiol.
(2003) - et al.
Right ventriculo-arterial coupling in pulmonary hypertension: a magnetic resonance study
Heart
(2012)
Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension
Eur. Heart J.
RV–pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension
Heart
Guidelines for the diagnosis and treatment of pulmonary hypertension
Eur. Respir. J.
Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging
J. Cardiovasc. Magn. Reson.
Measuring the heart in pulmonary arterial hypertension (PAH): implications for trial study size
J. Magn. Reson. Imaging
Cited by (90)
Optimizing Hemodynamic Interventricular Interactions in LVAD Recipients: Is Speed Everything?
2024, JACC: Heart FailureSleep-Related Hypoxia, Right Ventricular Dysfunction, and Survival in Patients With Group 1 Pulmonary Arterial Hypertension
2023, Journal of the American College of CardiologyClinical Value of a Novel Three-Dimensional Echocardiography–Derived Index of Right Ventricle–Pulmonary Artery Coupling in Tricuspid Regurgitation
2023, Journal of the American Society of EchocardiographyPulmonary artery pressure-directed therapies in pulmonary arterial hypertension?
2022, Vascular PharmacologyLeft ventricular dysfunction and intra-ventricular dyssynchrony in idiopathic pulmonary arterial hypertension
2022, International Journal of Cardiology